2,212 results match your criteria Neuro-Oncology[Journal]


Old meet new-the path to combination treatments in pediatric low-grade gliomas.

Neuro Oncol 2018 Dec 11. Epub 2018 Dec 11.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

View Article
December 2018

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Neuro Oncol 2018 Nov 30. Epub 2018 Nov 30.

Kurume University School of Medicine, Fukuoka, Japan.

Background: We conducted a phase III trial of personalized peptide vaccination (PPV) for human leucocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality.

Methods: We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n=58) or the placebo (n=30) at a 2-to-1 ratio. Four of 12 warehouse peptides selected based on preexisting peptide-specific IgG levels or the corresponding placebos were injected 1/week for 12 weeks. Read More

View Article
November 2018
2 Reads

Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.

Neuro Oncol 2018 Nov 28. Epub 2018 Nov 28.

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Background: cIMPACT-NOW update 3 recognizes amplification of EGFR as one important aberration in diffuse gliomas (WHO grade II/III). While these recommendations endorse testing, a cost-effective, clinically relevant testing paradigm is currently lacking. Here, we use real-world clinical data to propose a financially effective diagnostic test-algorithm in the context of new guidelines. Read More

View Article
November 2018

Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.

Neuro Oncol 2018 Nov 28. Epub 2018 Nov 28.

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße, Hamburg, Germany.

Background: To determine the value of diffusion-weighted (DW) magnetic resonance imaging (MRI) for characterization of benign and malignant peripheral nerve sheath tumors (PNSTs) in patients with neurofibromatosis type 1 (NF1).

Methods: Twenty-six patients with NF1 and suspicion of malignant transformation of PNSTs were prospectively enrolled, and underwent DW MRI at 3T. For a set of benign (n=55) and malignant (n=12) PNSTs, functional MRI parameters were derived from both biexponential intravoxel incoherent motion (diffusion coefficient D and perfusion fraction f) and monoexponential data analysis (apparent diffusion coefficients (ADCs)). Read More

View Article
November 2018
1 Read

Disparities along the glioblastoma clinical trials landscape.

Neuro Oncol 2018 Nov 26. Epub 2018 Nov 26.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
November 2018

Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.

Neuro Oncol 2018 Nov 10. Epub 2018 Nov 10.

Radiation Oncology, Beaumont Health, Royal Oak, MI, USA.

Background: Although considerable progress has been made in understanding molecular alterations driving gliomagenesis, the diverse metabolic programs contributing towards the aggressive phenotype of glioblastoma remain unclear. The aim of this study was to define and provide molecular context to metabolic reprogramming driving gliomagenesis.

Methods: Integrative cross-platform analyses coupling global metabolomic profiling with genomics in patient-derived glioma (low-grade astrocytoma [LGA; n=28] and glioblastoma [n=80]) was performed. Read More

View Article
November 2018
1 Read

CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.

Neuro Oncol 2018 Nov 23. Epub 2018 Nov 23.

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière?Charles Foix, Paris, France.

View Article
November 2018

Corrigendum.

Neuro Oncol 2018 Nov 20. Epub 2018 Nov 20.

Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO l'Hospitalet, IDIBELL, Barcelona, Spain, Hospitalet de Llobregat, Spain.

View Article
November 2018

Corrigendum.

Authors:

Neuro Oncol 2018 Nov 17. Epub 2018 Nov 17.

View Article
November 2018

Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma.

Neuro Oncol 2018 Nov 19. Epub 2018 Nov 19.

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Background: The goal of this study was to evaluate outcomes in children with relapsed, molecularly-characterized intracranial ependymoma treated with or without craniospinal irradiation (CSI) as part of a course of repeat radiation therapy (re-RT).

Methods: This was a retrospective cohort study of 31 children. Patients with distant relapse received CSI as part of re-RT. Read More

View Article
November 2018
3 Reads

Differences in molecular profiles of glioblastomas according to location.

Authors:
Craig Horbinski

Neuro Oncol 2018 Nov 15. Epub 2018 Nov 15.

Department of Pathology, Northwestern University, Chicago, Illinois.

View Article
November 2018

Introduction of novel agents in the treatment of Primary CNS Lymphoma.

Neuro Oncol 2018 Nov 13. Epub 2018 Nov 13.

Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.

Novel insights into the pathophysiology of Primary Central Nervous System Lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Read More

View Article
November 2018
4 Reads

Lower-grade gliomas: the wrong target for bevacizumab.

Neuro Oncol 2018 Nov;20(12):1559-1560

Neuro-Oncology Department, The MD Anderson Cancer Center, Houston, Texas.

View Article
November 2018

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.

Neuro Oncol 2018 Nov;20(12):1652-1660

Miami Cancer Institute, Department of Radiation Oncology, Miami, Florida.

Background: Brain metastases are a common complication of renal cell carcinoma (RCC). Our group previously published the Renal Graded Prognostic Assessment (GPA) tool. In our prior RCC study (n = 286, 1985-2005), we found marked heterogeneity and variation in outcomes. Read More

View Article
November 2018
7 Reads

Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.

Neuro Oncol 2018 Nov 10. Epub 2018 Nov 10.

Division of Signal Transduction and Growth Control, DKFZ/ZMBH Alliance, Heidelberg, Germany.

Background: Treatment options of glioblastoma, the most aggressive primary brain tumor with frequent relapses and high mortality, are still very limited urgently calling for novel therapeutic targets. Expression of the glycoprotein podoplanin correlates with poor prognosis in various cancer entities including glioblastoma. Furthermore, podoplanin has been associated with tumor cell migration and proliferation in vitro; however, experimental data on its function in gliomagenesis in vivo is still missing. Read More

View Article
November 2018
3 Reads

Novel methods to diagnose leptomeningeal metastases in breast cancer.

Neuro Oncol 2018 Nov 10. Epub 2018 Nov 10.

Erasmus MC Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands.

Leptomeningeal metastases (LM) in breast cancer patients are rare but often accompanied by devastating neurological symptoms and carries a very poor prognosis, even if treated. To date, two diagnostic methods are clinically used to diagnose LM: gadolinium MRI of the brain and/or spinal cord and cytological examination of cerebrospinal fluid (CSF). Both techniques are however hampered by limited sensitivities, often leading to a long diagnostic process requiring repeated lumbar punctures and MRI examinations. Read More

View Article
November 2018
4 Reads

Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma.

Neuro Oncol 2018 Nov 12. Epub 2018 Nov 12.

Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Boston, MA.

Primary central nervous system (CNS) lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Read More

View Article
November 2018
8 Reads

Updates in prognostic markers for gliomas.

Neuro Oncol 2018 Nov;20(suppl_7):vii17-vii26

Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Gliomas are the most common primary malignant brain tumor in adults. The traditional classification of gliomas has been based on histologic features and tumor grade. The advent of sophisticated molecular diagnostic techniques has led to a deeper understanding of genomic drivers implicated in gliomagenesis, some of which have important prognostic implications. Read More

View Article
November 2018
4 Reads

Survivorship care planning and implementation in neuro-oncology.

Neuro Oncol 2018 Nov;20(suppl_7):vii40-vii46

Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Survivorship has become a significant topic within oncologic care. The tools and means by which the provision of survivorship care can be implemented and delivered are in development and are the focus of significant research oncology-wide. These tools and methods include innovations of survivorship care delivery, survivorship care plans, and improving communication among all stakeholders in an individual patient's care as the means to elevate health-related quality of life. Read More

View Article
November 2018
7 Reads

Survivorship in Neuro-Oncology.

Neuro Oncol 2018 Nov;20(suppl_7):vii4-vii5

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, UNITED STATES.

View Article
November 2018
4 Reads

Inflammation and Vascular Permeability Correlate With Growth in Sporadic Vestibular Schwannoma.

Neuro Oncol 2018 Nov 2. Epub 2018 Nov 2.

Manchester Centre for Clinical Neurosciences, Salford Royal NHS foundation trust, Manchester Academic Health Science Centre.

Background: Inflammation is hypothesized to be a key event in the growth of sporadic vestibular schwannoma (VS). In this study we sought to investigate the relationship between inflammation and tumor growth in vivo using the PET tracer 11C-(R)-PK11195 and dynamic contrast enhanced (DCE) MRI derived vascular biomarkers.

Methods: Nineteen patients with sporadic VS (8 static, 7 growing and 4 shrinking tumors), underwent prospective imaging with dynamic 11C-(R)-PK11195 PET and a comprehensive MR protocol; including high temporal resolution DCE-MRI in fifteen patients. Read More

View Article
November 2018
2 Reads
5.562 Impact Factor

Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.

Neuro Oncol 2018 Oct 22. Epub 2018 Oct 22.

The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, USA.

Background: Mutations in the promoter of telomerase reverse transcriptase (TERTp) and isocitrate dehydrogenase 1 (IDH1) offer objective markers to assist in classifying diffuse gliomas into genetic subgroups. However, traditional mutation detection techniques lack sensitivity, or have long turnaround times, or high costs. We developed GliomaDx, an allele-specific, locked nucleic acid (LNA)-based qPCR assay to overcome these limitations and sensitively detect TERTp and IDH mutations. Read More

View Article
October 2018
5 Reads

Multimodal Imaging-defined Subregions in Newly-diagnosed Glioblastoma: Impact on Overall Survival.

Neuro Oncol 2018 Oct 22. Epub 2018 Oct 22.

Department of Pediatrics, Wayne State University, Detroit, Michigan.

Background: Although glioblastomas are heterogeneous brain-infiltrating tumors, their treatment is mostly focused on the contrast-enhancing tumor mass. In this study, we combined conventional MRI, diffusion-weighted imaging (DWI), and amino acid PET to explore imaging-defined glioblastoma subregions and evaluate their potential prognostic value.

Methods: Contrast-enhanced T1, T2/FLAIR MR images, apparent diffusion coefficient (ADC) maps from DWI, and alpha-[ 11C]-methyl-L-tryptophan (AMT)-PET images were analyzed in 30 patients with newly-diagnosed glioblastoma. Read More

View Article
October 2018

Viral and other therapies for recurrent GBM: is a 24-month durable response unusual?

Neuro Oncol 2018 Oct 22. Epub 2018 Oct 22.

Division of Neurosurgery, University of Toronto, Toronto, CA.

A phase 1 trial of an engineered poliovirus for the treatment of rGBM (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks1. Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades2. These replication-competent (tumor-selective, oncolytic, replication-conditional) viruses or replication-defective viral vectors (gene therapy) deliver cytotoxic payloads to tumors, leading to immunogenic death and intratumoral inflammatory responses. Read More

View Article
October 2018
2 Reads

Supratotal Resection in Glioma: A Systematic Review.

Neuro Oncol 2018 Oct 15. Epub 2018 Oct 15.

Brain Tumor and NeuroOncology Center and Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA.

Background: Emerging evidence suggests survival benefit from resection beyond all MRI abnormalities present on T1-enhanced and T2-FLAIR modalities in glioma (supratotal resection); however, the quality of evidence is unclear. We addressed this question via systematic review of the literature.

Methods: EMBASE, MEDLINE, Scopus, and Web of Science databases were queried. Read More

View Article
October 2018
13 Reads

Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.

Neuro Oncol 2018 Oct 12. Epub 2018 Oct 12.

Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.

Background: We assessed population-level changes in glioblastoma survival between 2000 and 2013 in Finland, with focus on elderly patients (>70 years) in order to assess if changes in treatment of glioblastoma are reflected also in population-based survival rates.

Methods: We identified all patients (age ≥18 years) from the Finnish Cancer Registry (FCR) with a histopathological diagnosis of primary glioblastoma in 2000-2013. Patients were followed up until December 2015. Read More

View Article
October 2018

Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region.

Neuro Oncol 2018 Oct 5. Epub 2018 Oct 5.

Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Germany.

View Article
October 2018
24 Reads

Non-malignant and malignant meningioma incidence and survival in the elderly from 2005-2015 using the Central Brain Tumor Registry of the United States.

Neuro Oncol 2018 Oct 6. Epub 2018 Oct 6.

Department of Internal Medicine, Stanford University.

Background: Meningioma incidence increases significantly with age. In the expanding elderly population, we lack complete understanding of population-based trends in meningioma incidence/survival. We provide an updated, comprehensive analysis of meningioma incidence and survival for individuals aged over 65. Read More

View Article
October 2018
1 Read

N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Neuro Oncol 2018 Oct 1. Epub 2018 Oct 1.

Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Consortium (DKTK); German Cancer Research Center (DKFZ); Heidelberg, Germany.

Background: Patients with glioblastoma without O6-methyl guanine O6-methylatransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ). Trials aiming at replacing TMZ with targeted agents in unselected patient populations have failed to demonstrate any improvement of survival. Advances in molecular understanding and diagnostic precision enable identification of key genetic alterations in a timely manner and in principle allow treatments with targeted compounds based on molecular markers. Read More

View Article
October 2018
2 Reads

Combined Iron Oxide Nanoparticle Ferumoxytol and Gadolinium Contrast Enhanced MRI Defines Glioblastoma Pseudo-progression.

Neuro Oncol 2018 Oct 1. Epub 2018 Oct 1.

Neurology, Oregon Health and Science University, Portland OR.

Background: Noninvasively differentiating therapy-induced pseudo-progression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity mediated neuroinflammation; therefore, we hypothesized that combined ferumoxytol and gadolinium enhanced MRI could serve as a biomarker of glioblastoma pseudo-progression.

Methods: In this institutional review board approved, retrospective study, we analyzed ferumoxytol and gadolinium contrast enhanced T1-weighted 3T MRI in 45 patients with glioblastoma over multiple clinical time points. Read More

View Article
October 2018
1 Read

TERT, the target?

Neuro Oncol 2018 Nov;20(12):1561-1562

Department of Neurosurgery, Hopital Pitié-Salpetrière, APHP, Paris, France and Sorbonne Université and Inserm, ICM, Paris, France.

View Article
November 2018
8 Reads

Outcomes following SRS for small- to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.

Neuro Oncol 2018 Sep 28. Epub 2018 Sep 28.

Department of Radiation Oncology, University of Toronto, Toronto, CANADA.

Background: At our institution, we have historically treated brain metastasis (BM) ≤2cm in eloquent brain with a radiosurgery (SRS) lower prescription dose (PD) to reduce the risk of radionecrosis (RN). We sought to evaluate the impact of this practice on outcomes.

Methods: We analyzed a prospective registry of BM patients treated with SRS between 2008 and 2017. Read More

View Article
September 2018
22 Reads
5.560 Impact Factor

Sex difference of mutation clonality in diffuse glioma evolution.

Neuro Oncol 2018 Sep 25. Epub 2018 Sep 25.

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China.

Background: x differences in glioma incidence and outcome have been previously reported but remain poorly understood. Many sex differencesthat affect the cancer risk were thought to be associated with cancer evolution.

Material/methods: In this study, we used an integrated framework to infer the timing and clonal status of mutations in ~600 diffuse gliomas from The Cancer Genome Atlas including glioblastomas (GBM) and low grade gliomas (LGG), and investigated the sex difference of mutation clonality. Read More

View Article
September 2018
1 Read

DNA-methylation profiling is a method of choice for molecular verification of pediatric WNT activated medulloblastomas.

Neuro Oncol 2018 Sep 25. Epub 2018 Sep 25.

Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

Background: WNT activated medulloblastoma (WNT MB) represent a well-characterized molecular variant accounting for 10-15% of all MB and is associated with a favorable clinical outcome. Patients with localized WNT MBs could benefit from de-intensification of combined treatment, which would require an accurate diagnosis of these tumors. However, despite the presence of molecular features related with a WNT MB signature (nuclear ß-catenin immunoexpression, CTNNB1 mutation and monosomy 6), a prompt and reliable diagnostic verification of these tumors is not yet feasible. Read More

View Article
September 2018
3 Reads

mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.

Neuro Oncol 2018 Sep 18. Epub 2018 Sep 18.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Background: Pediatric low-grade glioma (pLGG) often initially respond to front-line therapies such as carboplatin, but more than 50% of treated tumors eventually progress and require additional therapy. The discovery that pLGG often contain mammalian Target of Rapamycin (mTOR) activation, new treatment modalities and combinations are now possible for patients. The purpose of this study was to determine if carboplatin is synergistic with the mTORC1 inhibitor everolimus in pLGG. Read More

View Article
September 2018

Population description and clinical response assessment for spinal metastases: the SPINO group report.

Neuro Oncol 2018 Aug;20(9):1149

Department of Neurosurgery, Rhode Island Hospital/Warren Alpert School of Medicine at Brown University, Providence, Rhode Island.

View Article

Uncommon low-grade brain tumors.

Neuro Oncol 2018 Sep 20. Epub 2018 Sep 20.

Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, UK.

Search Strategy And Selection Criteria: An initial search of PubMed used broad search terms 'brain tumors', 'low-grade', 'radiotherapy, 'chemotherapy', 'surgery' and 'treatment' from January 1990 to March 2018. A subsequent focused search was undertaken using the names of individual histological subtypes of low-grade brain tumors as in the 2016 WHO classification. Only papers published in English were reviewed. Read More

View Article
September 2018
9 Reads

The subventricular zone concept: ready for therapeutic implications?

Neuro Oncol 2018 Oct;20(11):1423-1424

Department of Radiation Oncology, Gustave Roussy University Hospital, Villejuif, France.

View Article
October 2018
1 Read

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Neuro Oncol 2018 Sep 5. Epub 2018 Sep 5.

Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Read More

View Article
September 2018
9 Reads
5.562 Impact Factor

Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide.

Neuro Oncol 2018 Sep 3. Epub 2018 Sep 3.

Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: Isocitrate Deyhydrogenase (IDH) mutant gliomas are comprised of the majority of grade II-III gliomas and nearly all secondary glioblastomas. These progressive gliomas arise from mutations in IDH1 or IDH2 that pathologically produces D-2-hydroxyglutarate (2HG). 2-HG interferes with cell reactions using alpha ketoglutarate leading to a hypermethylated genome and epigenetic dysregulation of gene expression initiating tumorigenesis. Read More

View Article
September 2018

Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics.

Neuro Oncol 2018 Nov;20(12):1682-1683

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

View Article
November 2018
4 Reads

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy.

Neuro Oncol 2018 Aug 28. Epub 2018 Aug 28.

Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA.

Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG tumors cannot be surgically resected. Read More

View Article
August 2018
26 Reads

Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series.

Neuro Oncol 2018 Nov;20(12):1625-1633

Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Background: The genomic characterization of sporadically arising gliomas has delineated molecularly and clinically distinct subclasses of disease. However, less is known about the molecular nature of gliomas that are familial in origin. We performed molecular subtyping of 163 tumor specimens from individuals with a family history of glioma and integrated germline and somatic genomic data to characterize the pathogenesis of 20 tumors in additional detail. Read More

View Article
November 2018
2 Reads

Health insurance and the ongoing debate of quality and quantity.

Authors:
Robert Cavaliere

Neuro Oncol 2018 Sep;20(10):1287-1288

Baptist MD Anderson Cancer Center, Jacksonville, Florida.

View Article
September 2018

Revival of the VEGF ligand family?

Authors:
Simone P Niclou

Neuro Oncol 2018 Oct;20(11):1421-1422

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg.

View Article
October 2018
1 Read

First results on the DCVax phase III trial: raising more questions than providing answers.

Neuro Oncol 2018 Sep;20(10):1283-1284

Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

View Article
September 2018
3 Reads

Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology (RANO) Working Group.

Neuro Oncol 2018 Aug 18. Epub 2018 Aug 18.

Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma and there is no consensus on the optimal endpoints for trials currently underway. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. Read More

View Article
August 2018
1 Read

Sex-specific gene and pathway modeling of inherited glioma risk.

Neuro Oncol 2018 Aug 14. Epub 2018 Aug 14.

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States.

Background: To date, genome-wide association studies (GWAS) have identified 25 risk variants for glioma, explaining 30% of heritable risk. Most histologies occur with significantly higher incidence in males, and this difference is not explained by currently-known risk factors. A previous GWAS identified sex-specific glioma risk variants, and this analysis aims to further elucidate risk variation by sex using gene- and pathway-based approaches. Read More

View Article
August 2018
18 Reads